PURPOSE: The CD47 molecule, often referred to as the "do not eat me" signal, is frequently overexpressed in tumor cells. This signaling pathway limits phagocytosis by macrophages. Our objective was to determine CD47 abundance in various soft tissue sarcomas (STS) to investigate whether it could serve as a potential evasion mechanism for tumor cells. Additionally, we aimed to assess the prognostic value of CD47 expression by examining its association with different clinicopathological factors. This study aimed to elucidate the significance of CD47 in the context of emerging anti-tumor targeting approaches. METHODS: In this retrospective study, formalin-fixed paraffine-embedded (FFPE) tumor tissues of 55 treatment-naïve patients were evaluated by immunohistochemistry for the abundance of CD47 molecule on tumor cells. The categorization of CD47 positivity was as follows: 0 (no staining of tumor cells), 1 + (less than 1/3 of tumor area positive), 2 + (between 1/3 and 2/3 of tumor area positive), and 3 + (more than 2/3 of tumor area positive for CD47). Next, we compared CD47 abundance between different tumor grades (G1-3). We used Kaplan-Meier survival curves with log-rank test to analyze the differences in survival between patients with different CD47 expression. Moreover, we performed Cox proportional hazards regression model to evaluate the clinical significance of CD47. RESULTS: CD47 is widely prevalent across distinct STS subtypes. More than 80% of high grade undifferentiated pleiomorphic sarcoma (UPS), 70% of myxofibrosarcoma (MFS) and more than 60% of liposarcoma (LPS) samples displayed a pattern of moderate-to-diffuse positivity. This phenomenon remains consistent regardless of the tumor grade. However, there was a tendency for higher CD47 expression levels in the G3 group compared to the combined G1 + G2 groups when all LPS, MFS, and UPS were analyzed together. No significant associations were observed between CD47 abundance, death, and metastatic status. Additionally, high CD47 expression was associated with a statistically significant increase in progression-free survival in the studied cohort of patients. CONCLUSION: This study highlights the potential of the CD47 molecule as a promising immunotherapeutic target in STS, particularly given its elevated expression levels in diverse sarcoma types. Our data showed a notable trend linking CD47 expression to tumor grade, while also suggesting an interesting correlation between enhanced abundance of CD47 expression and a reduced hazard risk of disease progression. Although these findings shed light on different roles of CD47 in STS, further research is crucial to assess its potential in clinical settings.

3rd Department of Surgery 1st Faculty of Medicine Charles University and University Hospital Motol 5 Uvalu 84 150 06 Prague Czech Republic

Department of Immunology 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Uvalu 84 150 06 Prague 5 Czech Republic

Department of Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Uvalu 84 150 06 Prague Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Uvalu 84 150 06 Prague Czech Republic

Zobrazit více v PubMed

Banks LB, D’Angelo SP. The role of immunotherapy in the management of soft tissue sarcomas: current landscape and future outlook. J Natl Compr Canc Netw. 2022;20(7):834–844. doi: 10.6004/jnccn.2022.7027. PubMed DOI

Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing natural killer cells in the tumor microenvironment-the next generation of immunotherapy? Front Immunol. 2020;11:275. doi: 10.3389/fimmu.2020.00275. PubMed DOI PMC

Brightwell RM, Grzankowski KS, Lele S, Eng K, Arshad M, Chen H, Odunsi K. The CD47 “don’t eat me signal” is highly expressed in human ovarian cancer. Gynecol Oncol. 2016;143(2):393–397. doi: 10.1016/j.ygyno.2016.08.325. PubMed DOI PMC

Brom VC, Burger C, Wirtz DC, Schildberg FA. The role of immune checkpoint molecules on macrophages in cancer, infection, and autoimmune pathologies. Front Immunol. 2022;13:837645. doi: 10.3389/fimmu.2022.837645. PubMed DOI PMC

Chawla SP, Kelly CM, Gordon EM, Quon DV, Moradkhani A, Chua-Alcala VS, Thompson TM, Scheuber A, Bruns I, Allgood VE, Movva S. TTI-621–03: a phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS) J Clin Oncol. 2022 doi: 10.1200/JCO.2022.40.16_suppl.TPS11593. PubMed DOI

D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–426. doi: 10.1016/S1470-2045(18)30006-8. PubMed DOI PMC

Dancsok AR, Gao D, Lee AF, Steigen SE, Blay J-Y, Thomas DM, Maki RG, Nielsen TO, Demicco EG. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020;9(1):1747340. doi: 10.1080/2162402X.2020.1747340. PubMed DOI PMC

Edris B, Weiskopf K, Volkmer AK, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA. 2012;109(17):6656–6661. doi: 10.1073/pnas.1121629109. PubMed DOI PMC

Hai Z, Shucheng C, Junwei M, Hongwei X, Zhiyong Y. CD47 as a promising therapeutic target in oncology. Front Immunol. 2022 doi: 10.3389/fimmu.2022.757480. PubMed DOI PMC

Hayat SMG, Bianconi V, Pirro M, Jaafari MR, Hatamipour M, Sahebkar A. CD47: role in the immune system and application to cancer therapy. Cell Oncol. 2020;43(1):19–30. doi: 10.1007/s13402-019-00469-5. PubMed DOI

Huang J, Liu F, Li C, Liang X, Li C, Liu Y, Yi Z, Zhang L, Fu S, Zeng Y. Role of CD47 in tumor immunity: a potential target for combination therapy. Sci Rep. 2022 doi: 10.1038/s41598-022-13764-3. PubMed DOI PMC

Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, Guegan JP, Rey C, Sautès-Fridman C, Bougoüin A, Cantarel C, Kind M, Spalato M, Dadone-Montaudie B, Le Loarer F, Fridman WH. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022 doi: 10.1038/s41591-022-01821-3. PubMed DOI

Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J-Y, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PCW. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423. doi: 10.1016/S1470-2045(14)70063-4. PubMed DOI

Kelany M, Barth FE. Prevalence and prognostic implications of PD-L1 expression in soft tissue sarcomas. Pathol Oncol Res. 2021 doi: 10.3389/pore.2021.1609804. PubMed DOI PMC

Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Tawbi HA. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res. 2020;26(6):1258–1266. doi: 10.1158/1078-0432.CCR-19-1824. PubMed DOI PMC

Kitai Y, Ishiura M, Saitoh K, Matsumoto N, Owashi K, Yamada S, Muromoto R, Kashiwakura J, Oritani K, Matsuda T. CD47 promotes T-cell lymphoma metastasis by up-regulating AKAP13-mediated RhoA activation. Int Immunol. 2021;33(5):273–280. doi: 10.1093/intimm/dxab002. PubMed DOI

Klaver Y, Rijnders M, Oostvogels A, Wijers R, Smid M, Grünhagen D, Verhoef C, Sleijfer S, Lamers C, Debets R. Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. J Immunother Cancer. 2020;8(2):e000271. doi: 10.1136/jitc-2019-000271. PubMed DOI PMC

Lee JB, Kim HR, Ha S-J. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 2022 doi: 10.4110/in.2022.22.e2. PubMed DOI PMC

Li R-H, Zhou Q, Li A-B, Zhang H-Z, Lin Z-Q. A nomogram to predict metastasis of soft tissue sarcoma of the extremities. Medicine. 2020;99(21):e20165. doi: 10.1097/MD.0000000000020165. PubMed DOI PMC

Li Z, Li Y, Gao J, Fu Y, Hua P, Jing Y, Cai M, Wang H, Tong T. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sci. 2021;273:119150. doi: 10.1016/j.lfs.2021.119150. PubMed DOI

Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022 doi: 10.1038/s41573-022-00520-5. PubMed DOI PMC

Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol. 2019;20(1):6. doi: 10.1007/s11864-019-0606-9. PubMed DOI

Myint ZW, Chahine Z, Jayswal R, Bachert E, McDonald RJ, Strup SE, James AC, Hensley PJ, Allison DB. Association of CD47 expression with clinicopathologic characteristics and survival outcomes in muscle invasive bladder cancer. J Pers Med. 2023 doi: 10.3390/jpm13060885. PubMed DOI PMC

Nath PR, Pal-Nath D, Kaur S, Gangaplara A, Meyer TJ, Cam MC, Roberts DD. Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice. OncoImmunology. 2022;11(1):2111909. doi: 10.1080/2162402X.2022.2111909. PubMed DOI PMC

Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-Hofmann A, Grünewald TGP, Knösel T. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunol, Immunother CII. 2020;69(7):1353–1362. doi: 10.1007/s00262-020-02552-5. PubMed DOI PMC

Ozaniak A, Smetanova J, Bartolini R, Rataj M, Capkova L, Hacek J, Fialova M, Krupickova L, Striz I, Lischke R, Bartunkova J, Strizova Z. A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade. J Cancer Res Clin Oncol. 2022 doi: 10.1007/s00432-022-04292-8. PubMed DOI PMC

Petitprez F, de Reyniès A, Keung EZ, Chen TW-W, Sun C-M, Calderaro J, Jeng Y-M, Hsiao L-P, Lacroix L, Bougoüin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Fridman WH. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556–560. doi: 10.1038/s41586-019-1906-8. PubMed DOI

Resag A, Toffanin G, Benešová I, Müller L, Potkrajcic V, Ozaniak A, Lischke R, Bartunkova J, Rosato A, Jöhrens K, Eckert F, Strizova Z, Schmitz M. The immune contexture of liposarcoma and its clinical implications. Cancers. 2022 doi: 10.3390/cancers14194578. PubMed DOI PMC

Sbaraglia M, Bellan E. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113:70–84. doi: 10.32074/1591-951X-213. PubMed DOI PMC

Sercan Ç, Haberal Reyhan AN, Özen Ö, Ayhan A. Clinicopathologic and prognostic significance of CD47 expression and tumor-associated macrophages in endometrial carcinoma. Int J Gynecol Pathol. 2022;41(4):397–406. doi: 10.1097/PGP.0000000000000809. PubMed DOI

Strizova Z, Benesova I, Bartolini R, Novysedlak R, Cecrdlova E, Foley LK, Striz I. M1/M2 macrophages and their overlaps – myth or reality? Clin Sci. 2023;137(15):1067–1093. doi: 10.1042/CS20220531. PubMed DOI PMC

Tanaka K, Miyoshi H, Kawamoto K, Shimasaki Y, Nakashima K, Imamoto T, Yamada K, Takeuchi M, Moritsubo M, Furuta T, Kohno K, Tamura S, Sonoki T, Ohshima K. Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor. Pathology. 2024;56(1):81–91. doi: 10.1016/j.pathol.2023.10.007. PubMed DOI

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D’Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–1501. doi: 10.1016/S1470-2045(17)30624-1. PubMed DOI PMC

Toulmonde M, Lucchesi C, Verbeke S, Crombe A, Adam J, Geneste D, Chaire V, Laroche-Clary A, Perret R, Bertucci F, Bertolo F, Bianchini L, Dadone-Montaudie B, Hembrough T, Sweet S, Kim YJ, Cecchi F, Loarer FL, Italiano A. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. eBioMedicine. 2020 doi: 10.1016/j.ebiom.2020.103131. PubMed DOI PMC

Tsagozis P, Augsten M, Zhang Y, Li T, Hesla A, Bergh J, Haglund F, Tobin NP, Ehnman M. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. Cancer Immunol Immunother CII. 2019;68(6):927–936. doi: 10.1007/s00262-019-02322-y. PubMed DOI PMC

van Duijn A, der Burg SHV, Scheeren FA. CD47/SIRPα axis: bridging innate and adaptive immunity. J Immunother Cancer. 2022;10(7):e004589. doi: 10.1136/jitc-2022-004589. PubMed DOI PMC

Zhao H, Wang J, Kong X, Li E, Liu Y, Du X, Kang Z, Tang Y, Kuang Y, Yang Z, Zhou Y, Wang Q. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. Sci Rep. 2016 doi: 10.1038/srep29719. PubMed DOI PMC